CJC-1295 (No DAC) 60mg — Vial Spec, Reconstitution Math & COA

60mg Bulk Packaging Overview & Facility Supply Protocols

A 60mg vial of CJC-1295 (No DAC)—chemically categorized as Modified GRF (1-29)—contains 60 milligrams of high-purity lyophilized peptide cake synthesized as an acetate salt. This bulk format is specifically engineered for laboratory research environments conducting large-scale preclinical trials, high-density receptor binding studies, or longitudinal tissue repair experiments across extensive rodent cohorts. Utilizing a single 60mg lot minimizes experimental variance across multi-week assay schedules by eliminating inter-vial batch variations common in smaller packaging formats.

While standard single-study protocols generally utilize 2mg or 5mg packaging configurations available in our standard all-peptides directory and dedicated CJC-1295 (No DAC) product page, the 60mg fill size serves high-throughput laboratories and institutional core facilities. Principal investigators requiring bulk packaging or specialized fill volumes can coordinate custom multi-gram or 60mg lot runs through our specialized wholesale services portal. All PX1 Research compounds are manufactured in domestic, GMP-compliant facilities subject to stringent ISO 17025 analytical verification.

Molecular Structure, Receptor Kinetics & Preclinical Role

CJC-1295 (No DAC) is a synthetic 29-amino-acid tetrasubstituted peptide analog derived from native Growth Hormone-Releasing Hormone (GHRH 1-29). The chemical structure incorporates four targeted amino acid substitutions—D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These specific structural modifications significantly enhance metabolic stability against enzymatic cleavage, particularly by dipeptidyl peptidase-IV (DPP-IV), while preserving full biological affinity for the pituitary GHRH receptor (GHRHR).

In preclinical models, CJC-1295 (No DAC) functions as a potent GHRH receptor agonist. Unlike DAC (Drug Affinity Complex) conjugated variants that form covalent bonds with serum albumin to extend plasma half-life over several days, the non-DAC form exhibits a shorter, pulsatile pharmacokinetic profile with an elimination half-life of approximately 30 minutes in animal models. Research literature indicates that this pulsatile signaling mechanism closely mimics endogenous GHRH secretion patterns, stimulating physiological growth hormone (GH) release and downstream insulin-like growth factor 1 (IGF-1) expression without causing continuous, non-physiological receptor desensitization.

Reconstitution Mathematics & Volumetric Concentration Matrix

Reconstituting a 60mg bulk lyophilized vial requires careful planning to achieve target micro-concentrations suitable for precision pipetting. Because 60mg represents a substantial mass of active peptide, solvent selection and volumetric accuracy directly impact experimental reproducibility. Standard reconstitution solvents include Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose laboratory workflows or Sterile 0.9% Sodium Chloride / Phosphate-Buffered Saline (PBS) for alcohol-sensitive in vitro assays.

To calculate exact concentrations based on added diluent volume, researchers can utilize the following reference parameters or verify custom metrics using the PX1 reconstitution calculator:

1. Reconstitution with 1.0 mL Diluent: Yields a final concentration of 60.0 mg/mL (60.0 µg/µL). This hyper-concentrated stock is ideal for master stock preparation intended for subsequent serial dilutions into cell culture media or assay buffers.

2. Reconstitution with 2.0 mL Diluent: Yields a final concentration of 30.0 mg/mL (30.0 µg/µL). Provides high mass density while maintaining moderate viscosity for reliable manual pipetting.

3. Reconstitution with 3.0 mL Diluent: Yields a final concentration of 20.0 mg/mL (20.0 µg/µL). Excellent balance for multi-animal dosing calculations in high-density rodent models.

4. Reconstitution with 5.0 mL Diluent: Yields a final concentration of 12.0 mg/mL (12.0 µg/µL). Standard working stock concentration for high-volume automated liquid handling systems.

5. Reconstitution with 6.0 mL Diluent: Yields a final concentration of 10.0 mg/mL (10.0 µg/µL). Simplifies mathematical conversions for bench top research protocols requiring round metric units.

Aliquot Management & Freeze-Thaw Prevention Protocols

To maintain the structural integrity of CJC-1295 (No DAC) following reconstitution of a 60mg bulk vial, establishing a strict sub-aliquoting protocol is essential. Subjecting peptide solutions to repeated freeze-thaw cycles leads to ice crystal formation, physical shear stress, peptide aggregation, and accelerated peptide bond hydrolysis. Immediately following complete dissolution, working stocks should be split into single-use microcentrifuge tubes using low-binding polypropylene aliquoting containers.

When preparing aliquots for cell culture assays, researchers must consider solvent compatibility. Bacteriostatic water contains 0.9% benzyl alcohol, which serves as an effective preservative against microbial growth for up to 28 days under refrigeration (2–8°C). However, benzyl alcohol can introduce cytotoxic effects in sensitive cell lines during in vitro studies. For cell culture protocols, reconstitute the lyophilized cake in sterile phosphate-buffered saline (PBS, pH 7.4) or sterile water for injection, immediately aliquot into target working volumes, and store at -80°C until use.

Lyophilized and Solution Phase Storage Standards

Proper thermal management is critical to preserve the chemical potency and structural conformation of CJC-1295 (No DAC). Unreconstituted lyophilized vials should be stored in desiccated environments protected from direct light. Long-term storage guidelines dictate temperatures of -20°C for up to 24 months, or -80°C for extended research archival. Standard room temperature exposure during shipping or short-term laboratory transfer does not compromise stability, provided ambient conditions remain under 25°C for less than five consecutive days.

Once reconstituted, peptide stability depends heavily on temperature, pH, and preservative presence. Reconstituted solutions prepared with bacteriostatic water remain stable at 2°C to 8°C for up to 28 days. Solution phase samples lacking antimicrobial preservatives must be used immediately or sub-aliquoted and stored at -80°C, where they remain stable for up to 6 months. Reconstituted solutions should never be stored in frost-free freezers due to temperature fluctuation cycles that cause localized thawing and structural degradation.

Analytical Rigor: HPLC, Mass Spectrometry & COA Verification

PX1 Research enforces strict quality control parameters across every manufacturing batch. Each lot of CJC-1295 (No DAC) undergoes rigorous analytical testing prior to vial filling and release. Chemical purity is quantitatively verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum threshold of >98.0% monomeric purity without truncated fragment contamination.

Molecular identity is validated using Liquid Chromatography-Mass Spectrometry (LC-MS) to confirm the exact theoretical mass (3357.9 Da). Furthermore, because bacterial endotoxins can confound immunological and signaling studies in animal models, all PX1 lots undergo Chromogenic Limulus Amebocyte Lysate (LAL) testing to certify endotoxin content below 0.05 EU/mg. Institutional researchers can inspect or download lot-specific documentation directly via our dedicated COA verification library.

Comparative Analysis: GHRH Class Structural & Kinetic Differences

Evaluating secretagogue kinetics requires comparing CJC-1295 (No DAC) against structural and functional equivalents within the GHRH receptor agonist class. In preclinical secretagogue research, investigators frequently evaluate structural variations to determine receptor signaling intensity, degradation rates, and physiological downstream effects.

A common comparison involves CJC-1295 (No DAC) versus Sermorelin (native GHRH 1-29 fragment). While Sermorelin retains the exact sequence of natural GHRH, it is rapidly degraded by plasma DPP-IV, resulting in an in vivo half-life of roughly 8 to 12 minutes. In contrast, the tetrasubstituted backbone of CJC-1295 (No DAC) extends half-life to approximately 30 minutes, producing a more sustained GHRHR stimulation curve per molar equivalent. In dual-pathway axis studies, researchers frequently co-administer GHRH analogs alongside selective Growth Hormone Secretagogue Receptor (GHSR) agonists like Ipamorelin or GHRP-6 to observe synergistic, dual-receptor growth hormone release without causing premature receptor downregulation or elevated cortisol production.

Determining Optimal Fill Sizes: 2mg, 5mg vs. 60mg Bulk Yields

Selecting the appropriate vial fill size depends entirely on experimental design, assay duration, and cohort scale. Using an incorrect packaging size can lead to unnecessary peptide degradation from prolonged solution storage or excessive freeze-thaw cycles.

For small pilot studies, acute in vitro assays, or limited animal cohorts, standard 2mg or 5mg vials are highly efficient, ensuring complete reagent consumption within short operational windows. Conversely, multi-month longitudinal protocols, automated core facility screening pipelines, or large-cohort rodent trials benefit significantly from a single 60mg bulk batch. Reviewing comprehensive technical specifications across our broader research library helps research personnel select the precise volume, purity grade, and packaging configuration required for reproducible experimental outcomes.